Abstract:
The present invention is a method of incorporating a non-volatile memory into a CMOS process that requires four or fewer masks and limited additional processing steps. The present invention is an epi-silicon or poly-silicon process sequence that is introduced into a standard CMOS process (i) after the MOS transistors' gate oxide is formed and the gate poly-silicon is deposited (thereby protecting the delicate surface areas of the MOS transistors) and (ii) before the salicided contacts to those MOS transistors are formed (thereby performing any newly introduced steps having an elevated temperature, such as any epi-silicon or poly-silicon deposition for the formation of diodes, prior to the formation of that salicide). A 4F2 memory array is achieved with a diode matrix wherein the diodes are formed in the vertical orientation.
Abstract:
A memory-array decoder operably coupled to a memory array comprising a sequence of rows and receiving as input a plurality of address bits includes first and second decoder stages. The first decoder stage selects one or more first rows by decoding a first subset of the address bits, and the second decoder stage selects one or more second rows based on locations, within the sequence, of one or more third rows different from the one or more second rows.
Abstract:
An ophthalmic pharmaceutical composition useful in the treatment of glaucoma and control of intraocular pressure comprising an effective amount of a selective modulator of ALK5 receptor activity is disclosed. Also disclosed is a method of treating glaucoma and controlling intraocular pressure comprising applying a therapeutically effective amount of a pharmaceutical composition comprising a selective modulator of ALK5 receptor activity to an affected eye of a patient.
Abstract:
A high density memory device is fabricated three dimensionally in layers. To keep points of failure low, address decoding circuits are included within each layer so that, in addition to power and data lines, only the address signal lines need be interconnected between the layers.
Abstract:
A memory device includes a substrate, and, disposed thereover, an array of vertical memory switches. In some embodiments, each switch has at least three terminals and a cross-sectional area less than 6F2.
Abstract:
RNA interference is provided for inhibition of connective tissue growth factor mRNA expression in ocular disorders involving CTGF expression. Ocular disorders involving aberrant CTGF expression include glaucoma, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and wound healing. Such disorders are treated by administering interfering RNAs of the present invention.
Abstract:
A high-density memory device is fabricated three-dimensionally in layers. To keep points of failure low, address decoding circuits are included within each layer so that, in addition to power and data lines, only the address signal lines need be interconnected between the layers.
Abstract:
A communication technique enables the efficient transmission of data through a low bandwidth and/or time delayed communication link and minimizes the idle time of the communication link by using a deferred acknowledgment of message bundles to temporally pack the communication link. The transmitting system stores messages to be transmitted in a pending message queue and applies a dynamic window to the pending message queue to define a message bundle to be sent through the slow communication link. The transmitting system requests an acknowledgment for at least one message within the bundle, but does not require an acknowledgment for every message within the bundle. Transmitted messages are temporarily stored as outstanding messages in a retransmission queue until the transmitted messages are acknowledged or until a time-out period associated with the messages has lapsed. When the transmitting station receives a timely acknowledgment in response to a requested acknowledgment, the transmitting station removes all outstanding messages associated with that acknowledgment from the retransmission queue.
Abstract:
The present invention relates to methods to treat and/or prevent increased intraocular pressure in a subject by administering a protein kinase C-delta (PKCδ) inhibitor. In further embodiments, the present invention relates to methods to treat and/or prevent glaucoma by administering a PKCδ inhibitor.
Abstract:
An application programming interface schema, method and system for communicating between first and second application programming interfaces within a process control system includes processing a call from a first application programming interface for a data request, translating the data request from the first application programming interface into one or more methods of a unified application programming interface, and implementing the one or more methods of the unified application programming interface with a second application programming interface. A first unified layer receives a transmission request from a proprietary application programming interface, and translates the transmission request into one or more methods of a unified application programming interface. A second unified layer implements methods of the unified application programming interface with the wireless network application programming interface.